Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 19/20 | 0.88 |
| ▸ | PTK2B | Q14289 | 9/20 | 0.88 |
| ▸ | ULK1 | O75385 | 3/20 | 0.88 |
| ▸ | CDK1 | P06493 | 1/20 | 0.88 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.88 |
| ▸ | CDK7 | P50613 | 1/20 | 0.88 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060602 | 0.94 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL29382158 | 0.94 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5212404 | 0.94 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL31732817 | 0.94 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL6212081 | 0.93 | PTK2 (0.88) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5208623 | 0.91 | PTK2 (0.73) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL17545007 | 0.90 | PTK2 (0.92) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5215829 | 0.89 | PTK2 (0.70) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL3146424 | 0.88 | PTK2 (1.00) | PTK2PTK2BULK1CDK1CCNB1 | |
| SCHEMBL5210397 | 0.88 | PTK2 (0.80) | PTK2PTK2BULK1CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | claimed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2022-04-28 | — | — | US | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1758887-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Incorporated (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005111016-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125788-A1 | FAK inhibitor and drug combination thereof | CD274, PDCD1, PTK2 | PTK2 3/4885PTK2B 80/4885ULK1 880/4885 |
| US-20050256111-A1 | Pyrimidine derivatives for the treatment of abnormal cell growth | TYMS, TYMP, CCNA1 | PTK2 3610/4885PTK2B 3168/4885ULK1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.